Muhammad Irfan, MD
Internal Medicine · Tomball, TXNPI 1972570489
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.3% of the total across 244 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 11.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,222 and has fallen 61.7% since, to $469 in 2025.
Across 244 payments — averaging $17.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$506
- AstraZeneca$475
- Amarin Pharma, Inc.$364
- AbbVie$305
- Astellas Pharma US Inc$278
- Johnson & Johnson$272
- plus $2K from 35 others
Across 7,202 payments — averaging $4258.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$18.5M
- Pfizer$4.7M
- Emergent Biosolutions Inc.$999K
- Johnson & Johnson$962K
- Bavarian Nordic A/s$927K
- AbbVie$770K
- plus $3.8M from 15 others
What the payments were for
- Food & beverage$4,00791%
- Education$3819%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 25 | $506 |
| AstraZeneca | 24 | $475 |
| Amarin Pharma, Inc. | 18 | $364 |
| AbbVie(2 entities) | 18 | $305 |
| Astellas Pharma US Inc | 4 | $278 |
| Johnson & Johnson | 14 | $272 |
| Pfizer | 26 | $232 |
| Amgen | 13 | $223 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 19 | $219 |
| Lilly USA, LLC | 10 | $189 |
| Dexcom, Inc. | 8 | $147 |
| Bayer | 8 | $135 |
| Abbott | 8 | $127 |
| Esperion Therapeutics, Inc. | 3 | $69 |
| Radius Health, Inc. | 2 | $68 |
| Kowa Pharmaceuticals America, Inc. | 4 | $60 |
| Lundbeck LLC | 2 | $56 |
| GSK | 3 | $53 |
| Philips North America LLC | 3 | $47 |
| Mylan Specialty L.p. | 2 | $45 |
| Eisai Inc. | 2 | $45 |
| Merck | 3 | $42 |
| Sanofi-aventis U.S. LLC | 3 | $36 |
| Sanofi Pasteur Inc. | 2 | $32 |
| UCB, Inc. | 1 | $32 |
| Inspire Medical Systems, Inc. | 1 | $29 |
| Novartis | 2 | $28 |
| Valeritas, Inc. | 1 | $27 |
| Genentech USA, Inc. | 2 | $26 |
| Sunovion Pharmaceuticals Inc. | 2 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
| Corcept Therapeutics | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Avanir Pharmaceuticals, Inc. | 1 | $19 |
| Neurocrine Biosciences, Inc. | 1 | $18 |
| Exact Sciences | 1 | $17 |
| Medtronic | 1 | $15 |
| Boehringer Ingelheim | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$123
How this compares
$4,389 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 225 | $163,192 |
| OzempicSemaglutide | 165 | $161,807 |
| FarxigaDapagliflozin Propanediol | 112 | $102,093 |
| JardianceEmpagliflozin | 95 | $86,658 |
| MounjaroTirzepatide | 66 | $67,138 |
| XareltoRivaroxaban | 55 | $53,669 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 64 | $48,512 |
| XifaxanRifaximin | 12 | $44,579 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 43 | $36,481 |
| JanuviaSitagliptin Phosphate | 24 | $31,721 |
| TrulicityDulaglutide | 21 | $30,111 |
| Xigduo XrDapaglifloz Propaned/Metformin | 20 | $23,819 |
| EntrestoSacubitril/Valsartan | 16 | $23,192 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 36 | $22,979 |
| VascepaIcosapent Ethyl | 46 | $21,760 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $232 | $163,192225 claims |
| Novo NordiskOzempic | $506 | $161,807165 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Combivent Respimat | $14 | $149,370183 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Brilinta | $475 | $147,642229 claims |
| Lilly USA, LLCMounjaro, Trulicity | $189 | $97,24987 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $53 | $57,11887 claims |
| Johnson & JohnsonXarelto | $272 | $53,66955 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $219 | $44,57912 claims |
| MerckJanuvia | $42 | $31,72124 claims |
| NovartisEntresto | $28 | $23,19216 claims |
| AbbVieLinzess | $305 | $21,00223 claims |
| Astellas Pharma US IncMyrbetriq | $278 | $20,83634 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Tomball
- Spencer BerthelsenSugar Land$891K
- Hameed AliTemple$773K
- Marc TribbleDallas$693K
- Gary SinclairDallas$599K
- Mohammed Al-NajjarEl Paso$586K
- Han SchmidlyDallas$465K
- Hussein TawbiHouston$365K
- Hans LeeHouston$327K
- Tapan KadiaHouston$311K
- Nitin JainHouston$281K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.